vs
Willdan Group, Inc.（WLDN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Willdan Group, Inc.的季度营收约是再鼎医药的1.4倍（$182.0M vs $127.1M），再鼎医药同比增速更快（17.1% vs 15.0%），Willdan Group, Inc.自由现金流更多（$9.8M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 8.1%）
Willdan集团是美国上市的专业技术与咨询服务提供商，服务对象覆盖公共及私营公用事业企业、各级政府公共机构，还有工商业领域客户。公司在全美十余个州设有办事处，核心业务布局于加利福尼亚州与纽约州。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
WLDN vs ZLAB — 直观对比
营收规模更大
WLDN
是对方的1.4倍
$127.1M
营收增速更快
ZLAB
高出2.1%
15.0%
自由现金流更多
WLDN
多$36.5M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
8.1%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $182.0M | $127.1M |
| 净利润 | $13.7M | — |
| 毛利率 | 36.9% | 51.0% |
| 营业利润率 | 8.2% | -54.6% |
| 净利率 | 7.5% | — |
| 营收同比 | 15.0% | 17.1% |
| 净利润同比 | 86.8% | — |
| 每股收益（稀释后） | $0.90 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收WLDNZLAB
| Q4 25 | $182.0M | $127.1M | ||
| Q3 25 | $173.5M | $115.4M | ||
| Q2 25 | $152.4M | $109.1M | ||
| Q1 25 | — | $105.7M | ||
| Q4 24 | $144.1M | $108.5M | ||
| Q3 24 | $158.3M | $101.8M | ||
| Q2 24 | $141.0M | $100.1M | ||
| Q1 24 | $122.5M | $87.1M |
净利润WLDNZLAB
| Q4 25 | $13.7M | — | ||
| Q3 25 | $15.4M | $-36.0M | ||
| Q2 25 | $4.7M | $-40.7M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | $7.7M | — | ||
| Q3 24 | $7.3M | $-41.7M | ||
| Q2 24 | $4.6M | $-80.3M | ||
| Q1 24 | $2.9M | $-53.5M |
毛利率WLDNZLAB
| Q4 25 | 36.9% | 51.0% | ||
| Q3 25 | 39.4% | 59.5% | ||
| Q2 25 | 37.8% | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | 38.1% | 61.5% | ||
| Q3 24 | 32.6% | 64.1% | ||
| Q2 24 | 34.6% | 64.9% | ||
| Q1 24 | 38.7% | 61.4% |
营业利润率WLDNZLAB
| Q4 25 | 8.2% | -54.6% | ||
| Q3 25 | 6.8% | -42.3% | ||
| Q2 25 | 4.6% | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | 7.5% | -62.6% | ||
| Q3 24 | 5.5% | -66.6% | ||
| Q2 24 | 4.6% | -76.0% | ||
| Q1 24 | 4.4% | -80.7% |
净利率WLDNZLAB
| Q4 25 | 7.5% | — | ||
| Q3 25 | 8.9% | -31.2% | ||
| Q2 25 | 3.1% | -37.3% | ||
| Q1 25 | — | -45.8% | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 4.6% | -40.9% | ||
| Q2 24 | 3.3% | -80.2% | ||
| Q1 24 | 2.4% | -61.4% |
每股收益（稀释后）WLDNZLAB
| Q4 25 | $0.90 | $-0.05 | ||
| Q3 25 | $1.03 | $-0.03 | ||
| Q2 25 | $0.32 | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | $0.53 | $-0.09 | ||
| Q3 24 | $0.51 | $-0.04 | ||
| Q2 24 | $0.33 | $-0.08 | ||
| Q1 24 | $0.21 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.1M | $689.6M |
| 总债务越低越好 | $49.1M | — |
| 股东权益账面价值 | $283.1M | $715.5M |
| 总资产 | $507.9M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资WLDNZLAB
| Q4 25 | $33.1M | $689.6M | ||
| Q3 25 | $32.3M | $717.2M | ||
| Q2 25 | $38.4M | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | $74.2M | $779.7M | ||
| Q3 24 | $53.1M | $616.1M | ||
| Q2 24 | $44.3M | $630.0M | ||
| Q1 24 | $46.9M | $650.8M |
总债务WLDNZLAB
| Q4 25 | $49.1M | — | ||
| Q3 25 | $59.7M | — | ||
| Q2 25 | $86.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $89.5M | — | ||
| Q3 24 | $91.9M | — | ||
| Q2 24 | $93.7M | — | ||
| Q1 24 | $95.5M | — |
股东权益WLDNZLAB
| Q4 25 | $283.1M | $715.5M | ||
| Q3 25 | $265.9M | $759.9M | ||
| Q2 25 | $245.5M | $791.7M | ||
| Q1 25 | — | $810.8M | ||
| Q4 24 | $234.3M | $840.9M | ||
| Q3 24 | $224.0M | $667.7M | ||
| Q2 24 | $213.0M | $704.2M | ||
| Q1 24 | $205.5M | $762.2M |
总资产WLDNZLAB
| Q4 25 | $507.9M | $1.2B | ||
| Q3 25 | $484.9M | $1.2B | ||
| Q2 25 | $471.2M | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $464.9M | $1.2B | ||
| Q3 24 | $447.3M | $985.3M | ||
| Q2 24 | $421.3M | $987.4M | ||
| Q1 24 | $407.9M | $988.4M |
负债/权益比WLDNZLAB
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.41× | — | ||
| Q2 24 | 0.44× | — | ||
| Q1 24 | 0.46× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.2M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $9.8M | $-26.7M |
| 自由现金流率自由现金流/营收 | 5.4% | -21.0% |
| 资本支出强度资本支出/营收 | 1.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.89× | — |
| 过去12个月自由现金流最近4个季度 | $65.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流WLDNZLAB
| Q4 25 | $12.2M | $-26.0M | ||
| Q3 25 | $25.4M | $-32.0M | ||
| Q2 25 | $3.3M | $-31.0M | ||
| Q1 25 | — | $-61.7M | ||
| Q4 24 | $33.5M | $-55.8M | ||
| Q3 24 | $10.8M | $-26.8M | ||
| Q2 24 | $889.0K | $-42.2M | ||
| Q1 24 | $26.9M | $-90.1M |
自由现金流WLDNZLAB
| Q4 25 | $9.8M | $-26.7M | ||
| Q3 25 | $23.2M | $-35.0M | ||
| Q2 25 | $1.0M | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | $31.1M | $-58.4M | ||
| Q3 24 | $8.8M | $-28.2M | ||
| Q2 24 | $-1.3M | $-42.9M | ||
| Q1 24 | $25.0M | $-91.1M |
自由现金流率WLDNZLAB
| Q4 25 | 5.4% | -21.0% | ||
| Q3 25 | 13.4% | -30.4% | ||
| Q2 25 | 0.7% | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | 21.6% | -53.8% | ||
| Q3 24 | 5.6% | -27.7% | ||
| Q2 24 | -0.9% | -42.9% | ||
| Q1 24 | 20.4% | -104.5% |
资本支出强度WLDNZLAB
| Q4 25 | 1.3% | 0.5% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | 1.6% | 2.4% | ||
| Q3 24 | 1.2% | 1.3% | ||
| Q2 24 | 1.5% | 0.7% | ||
| Q1 24 | 1.6% | 1.1% |
现金转化率WLDNZLAB
| Q4 25 | 0.89× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.35× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 0.19× | — | ||
| Q1 24 | 9.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
WLDN
| Public Utility | $74.2M | 41% |
| Governments | $64.6M | 35% |
| Engineering Consulting Services | $27.3M | 15% |
| Commercial | $15.9M | 9% |
| Alternative Power Generation Inc | $4.8M | 3% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
